Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Olema Pharmaceuticals, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on targeted therapies for breast cancer and its ongoing clinical trials [1] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company dedicated to improving outcomes for breast cancer patients through innovative therapies [3] - The company is advancing a pipeline that includes palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3] - Olema is also developing OP-3136, a potent lysine acetyltransferase 6 inhibitor, which is in a Phase 1 clinical study [3] - The company is headquartered in San Francisco with operations in Cambridge, Massachusetts [3]